Charles A. Leath

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

Robert L. Coleman, Gini F. Fleming, Mark F. Brady et al. · New England Journal of Medicine · 2019 · 886 citations · Full text

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum‐Gamez et al. · Journal of the National Comprehensive Cancer Network · 2021 · 688 citations · Full text

Surgical Oncology, Epithelial Ovarian Cancer, Cancer Management +19

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

Ramez N. Eskander, Michael W. Sill, Lindsey Beffa et al. · New England Journal of Medicine · 2023 · 626 citations · Full text

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022

Deborah K. Armstrong, Ronald D. Alvarez, Floor Backes et al. · Journal of the National Comprehensive Cancer Network · 2022 · 369 citations · Full text

Nccn Guidelines® Insights, Tumoral Pathology, Endocrine-related Cancer +13

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Robert L. Coleman, Domenica Lorusso, Christine Gennigens et al. · The Lancet Oncology · 2021 · 367 citations

Tisotumab Vedotin, Cervical Cancer, Metastatic Cervical Cancer +8